Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-13
DOI
10.1038/s41598-021-89684-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
- (2019) Qingbin Cui et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
- (2019) Kazuki Okubo et al. CANCER SCIENCE
- Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
- (2017) Jonathan A. Webster et al. LEUKEMIA RESEARCH
- Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor
- (2017) Ryan Montano et al. Oncotarget
- Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
- (2016) Matthew I. Milowsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
- (2016) Kathleen A. Bridges et al. Oncotarget
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
- (2015) Ching-Chia Li et al. Oncotarget
- Biology of the cell cycle inhibitor p21CDKN1A: molecular mechanisms and relevance in chemical toxicology
- (2014) Ilaria Dutto et al. ARCHIVES OF TOXICOLOGY
- Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors
- (2014) W-T Wang et al. ONCOGENE
- ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
- (2014) Camilo Guzmán et al. PLoS One
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
- (2013) Ryan Montano et al. BMC CANCER
- The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
- (2013) Y. Dai et al. MOLECULAR CANCER THERAPEUTICS
- p21 promotes error-free replication-coupled DNA double-strand break repair
- (2012) Maurizio Mauro et al. NUCLEIC ACIDS RESEARCH
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Comparison of nonhomologous end joining and homologous recombination in human cells
- (2008) Z MAO et al. DNA REPAIR
- Single-strand break repair and genetic disease
- (2008) Keith W. Caldecott NATURE REVIEWS GENETICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started